The Methodist Hospital System and Health Science University | Date: 2016-12-09
Cells are magnetized and then grown in ring shaped 3D culture using a ring magnet. Contractility is measuring by tracking the size of the hole in the 3D cellular ring.
News Article | May 4, 2017
The video commerce company participates in the annual star-studded event MINNEAPOLIS, May 04, 2017 (GLOBE NEWSWIRE) -- Evine Live Inc. (“Evine”) (NASDAQ:EVLV), a multiplatform video commerce company (evine.com), today announced that it will support the 24th annual Race to Erase MS Gala on May 5, held at The Beverly Hilton in Los Angeles. A platinum sponsor of the star-studded gala, Evine is making a financial donation as well as donating several auction items to help raise funds in the fight against multiple sclerosis (MS), a disease that impacts over 2 million people worldwide. Following the gala event, Nancy Davis will appear live on Evine on May 19 - 21 with her signature “Peace & Love” branded product, including a co-branded timepiece created in partnership with Invicta, Evine’s best-selling watch brand. “It is an honor for Evine to partner with Nancy Davis and the Race to Erase MS to help find a cure for multiple sclerosis,” said Bob Rosenblatt, Chief Executive Officer of Evine. “MS is a disease that impacts some of our closest vendors, investors and customers, and we are humbled to support such a worthy cause. I look forward to having the opportunity to demonstrate Evine’s ‘Be Good to Others’ mantra as we partner with Nancy to help support research toward eradicating this debilitating disease.” The Race to Erase MS was founded by Davis in 1993 after being diagnosed with the disease. Since 1994, the foundation has raise more than $46 million in contributions. Funding research is the core focus of the foundation, with all funds raised supporting the Center Without Walls program, a nationwide collaboration of physicians and scientists all working to find a cure. “When I was first diagnosed, there were no drugs on the market to help stop the progression of MS. Today, there are 15 FDA-approved drugs to treat the symptoms of MS, and the FDA recently approved Ocrevus, which helps people with relapsing remitting MS in addition to people with primary progressive MS,” said Nancy David, founder of Race to Erase MS and owner of Peace & Love Jewelry. “That progress gives me hope and makes me grateful for all the people and organizations who have supported the Race to Erase MS. Evine has been an amazing partner over the past two years. The company’s generosity and willingness to raise awareness and money for MS research keeps our hope for finding a cure alive.” Happening on Friday, May 5, the 24th annual Race to Erase MS Gala is a star-studded event frequented by some of the biggest names in Hollywood. This year’s event will honor Jamie-Lynn Sigler, most notably known for her role as Meadow Soprano on HBO’s “The Sopranos,” with the 2017 Medal of Hope Award. Evine will send its own star-power, with host Heather Hall interviewing attendees on the red carpet along with Dr. Terry and Heather Dubrow as guests of honor. In addition to the financial donation, Evine will also offer several auction items, including an “Evine Experience.” As part of the experience, the auction’s winner would receive a two-night travel package to Evine studios, including airfare and hotel for two. While at the studios, the winner would be given a backstage tour, the opportunity to pitch their product and a chance to sell a product live on Evine’s television network. Invicta, Evine’s best-selling watch brand, has also created a timepiece especially for Davis’ foundation. Based on the popular Invicta Peace & Love watch released in early 2015, this year’s Invicta Peace & Love Lupah will be offered in both men’s and women’s styles and include six additional easy-to-change colorful straps. Each timepiece proudly displays Nancy Davis’s signature Peace & Love logo on its dial and comes packaged in a specially-designed gift box. Returning to Evine May 19 at 8pm ET, May 20 at 1am, 3pm and 8pm ET, and May 21 throughout the day, Davis will present the co-branded watch and new pieces from her Peace & Love gemstone jewelry collection, including a white topaz and zircon adjustable bracelet, offered in 14 different styles. For more information on the Race to Erase MS, visit www.erasems.org. To bid on the “Evine Experience,” visit http://bit.ly/2oMxhPK. For more information on Evine and to shop Davis’ full collection, go to www.evine.com/peaceandlove. About Evine Evine Live Inc. (NASDAQ:EVLV) operates Evine, a multiplatform video commerce company that offers a compelling mix of proprietary and name brands directly to consumers in an engaging and informative shopping experience via television, online and mobile. Evine reaches approximately 87 million cable and satellite television homes 24 hours a day with entertaining content in a comprehensive digital shopping experience. About Race to Erase MS Race to Erase MS is dedicated to the treatment and ultimate cure for MS. Funding research is the core focus of the foundation and significant strides have been made to find the cause and cure of this debilitating disease. At the event’s inception 24 years ago, the absence of medications and therapies encouraged its involvement; the Race has been instrumental in funding many pilot studies that have contributed to drugs now on the market and other very important therapies that are improving the lives of people suffering from MS. All funds raised support the Center Without Walls program, a unique collaboration of the world’s leading MS research scientists currently representing Harvard, Yale, Cedars Sinai, University of Southern California, Oregon Health Science University, UC San Francisco and Johns Hopkins. This nationwide collaboration of physicians, scientists and clinicians are on the cutting-edge of innovative research and therapeutic approaches to treat MS. It is the hope of the Race to Erase MS that in addition to combating MS through research in a clinical environment, awareness will be created by educating the public about this mysterious disease. Tickets to the 24th Annual Race to Erase MS Gala start at $1,000 and tables start at $10,000. To purchase tickets for the event, please contact email@example.com or (310) 440-4842.
News Article | May 4, 2017
The ICP teaching laboratory spans nearly 7,000 square feet and allows for a broad range of physical therapy and occupational therapy classes in a hands-on learning environment. The Center provides various real-world settings for hands-on learning, including a 16-bed patient ward, a dedicated area for Occupational Therapy education, two patient assessment rooms which provide acute care and clinical scenarios, a complex simulation room, a 25 seat observation and debriefing room, and an activities of daily living lab with a kitchen, bedroom, dining, closet, bathroom and living area. The ICP has flexibility to adapt the spaces to meet simulation activity needs and includes state-of-the-art medical tools and resources that enable USAHS to educate the next generation of health care professionals. Simulation education's hands-on approach is a proven curriculum technique, laying the foundation for success. The features of simulation which best facilitate learning include the ability to provide feedback, curriculum integration, repetitive practice and the ability to range the difficulty levels. Importantly, simulated, hands-on education is proven to improve professional confidence, patient safety, communication and interpersonal skills, and allows students to quickly build trust with patients and their families. For more information on the San Marcos Center for Clinical Practice or USAHS, please visit usa.edu. About University of St. Augustine for Health Sciences (USAHS) The University of St. Augustine for Health Sciences (USAHS) is a graduate institution that offers degree programs in physical therapy, occupational therapy, nursing, education and health science, as well as continuing education programs. Founded in 1979, USAHS has locations in San Marcos, California; St. Augustine, Florida; Austin, Texas; and Miami, Florida. USAHS is regionally accredited by the Western Association of Schools and Colleges Senior College and University Commission. USAHS is one of more than 70 institutions in 25 countries that comprise the Laureate International Universities network. For more information about USAHS visit www.usa.edu. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/university-of-st-augustine-for-health-sciences-unveils-new-center-for-innovative-clinical-practice-icp-on-its-san-marcos-campus-300452043.html
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Armstrong T.S.,Health Science University
Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2013
Radiation Therapy Oncology Group trial 0525 tested whether dose-intensifying temozolomide versus standard chemoradiotherapy improves overall survival (OS) or progression-free survival (PFS) in newly diagnosed glioblastoma. Tests of neurocognitive function (NCF) and symptoms (using the MD Anderson Symptom Inventory-Brain Tumor module; MDASI-BT) and of quality of life (European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ] -C30/BN20) examined the net clinical benefit (NCB) of therapy. NCF tests (Hopkins Verbal Learning Test-Revised, Trail Making Test, and Controlled Oral Word Association), MDASI-BT, and EORTC QLQ-C30/BN20 were completed in a subset of patients. Multivariate Cox proportional hazard regression modeling determined the prognostic value of baseline and early change from baseline to cycle 1 for OS and PFS. Two-sample proportional test statistic was used to evaluate differences between treatments (dose-dense v standard-dose) on NCB measures from baseline to cycle 4 in stable patients. Overall, 182 patients participated in the study. Baseline NCF tests and the physical functioning quality of life scale were associated with OS and PFS. Baseline to cycle 1 in all NCB components were associated with OS and PFS. There was greater deterioration in the dose-dense arm from baseline to cycle 4 in the Global Health and Motor Function subscales (EORTC QLQ-C30/BN20) as well as in overall symptom burden, overall symptom interference, and activity-related symptom interference subscales (MDASI-BT). There were no between-arm differences in NCF. Longitudinal collection of NCB measures is feasible in cooperative group studies and provides an added dimension to standard outcome measures. Greater adverse symptom burden and functional interference, as well as decreased global health and motor function were observed in patients randomly assigned to the dose-dense arm. Baseline and early change in NCB measures were associated with decreased rates of survival.
O'Meara S.,Health Science University
Cochrane database of systematic reviews (Online) | Year: 2012
Up to one percent of people in industrialised countries will suffer from a leg ulcer at some time. The majority of these leg ulcers are due to problems in the veins, resulting in an accumulation of blood in the legs. Leg ulcers arising from venous problems are called venous (or varicose or stasis) ulcers. The main treatment is the application of a firm compression garment (bandage or stocking) in order to aid venous return. There is a large number of compression garments available and it was unclear whether they are effective in treating venous ulcers and, if so, which method of compression is the most effective. To undertake a systematic review of all randomised controlled trials (RCTs) evaluating the effects on venous ulcer healing of compression bandages and stockings.Specific questions addressed by the review are:1. Does the application of compression bandages or stockings aid venous ulcer healing? 2. Which compression bandage or stocking system is the most effective? For this second update we searched: the Cochrane Wounds Group Specialised Register (31 May 2012); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 5, 2012); Ovid MEDLINE (1950 to May Week 4 2012); Ovid MEDLINE (In-Process & Other Non-Indexed Citations 30 May 2012); Ovid EMBASE (1980 to 2012 Week 21); and EBSCO CINAHL (1982 to 30 May 2012). No date or language restrictions were applied. RCTs recruiting people with venous leg ulceration that evaluated any type of compression bandage system or compression stockings were eligible for inclusion. Eligible comparators included no compression (e.g. primary dressing alone, non-compressive bandage) or an alternative type of compression. RCTs had to report an objective measure of ulcer healing in order to be included (primary outcome for the review). Secondary outcomes of the review included ulcer recurrence, costs, quality of life, pain, adverse events and withdrawals. There was no restriction on date, language or publication status of RCTs. Details of eligible studies were extracted and summarised using a data extraction table. Data extraction was performed by one review author and verified independently by a second review author. Forty-eight RCTs reporting 59 comparisons were included (4321 participants in total). Most RCTs were small, and most were at unclear or high risk of bias. Duration of follow-up varied across RCTs. Risk ratio (RR) and other estimates are shown below where RCTs were pooled; otherwise findings refer to a single RCT.There was evidence from eight RCTs (unpooled) that healing outcomes (including time to healing) are better when patients receive compression compared with no compression.Single-component compression bandage systems are less effective than multi-component compression for complete healing at six months (one large RCT).A two-component system containing an elastic bandage healed more ulcers at one year than one without an elastic component (one small RCT).Three-component systems containing an elastic component healed more ulcers than those without elastic at three to four months (two RCTs pooled), RR 1.83 (95% CI 1.26 to 2.67), but another RCT showed no difference between groups at six months.An individual patient data meta-analysis of five RCTs suggested significantly faster healing with the four-layer bandage (4LB) than the short stretch bandage (SSB): median days to healing estimated at 90 and 99 respectively; hazard ratio 1.31 (95% CI 1.09 to 1.58).High-compression stockings are associated with better healing outcomes than SSB at two to four months: RR 1.62 (95% CI 1.26 to 2.10), estimate from four pooled RCTs.One RCT suggested better healing outcomes at 16 months with the addition of a tubular device plus single elastic bandage to a base system of gauze and crepe bandages when compared with two added elastic bandages.
Miller P.D.,Health Science University
American Journal of Kidney Diseases | Year: 2014
Osteoporosis is defined as a condition of impairment in bone strength due to low bone mineral density and poor bone quality and predisposes individuals to an increased risk of fractures. Osteoporosis may coexist with chronic kidney disease-mineral and bone disorder (CKD-MBD) and osteoporotic fractures occur in all stages of CKD. Management of osteoporosis in CKD should consider the pathophysiology of both disorders. Diagnosis and management of osteoporosis in patients with stages 1-3 CKD and patients without CKD are similar, but diagnosis and management decisions differ greatly once patients have stages 4-5 CKD. Discriminating between osteoporosis and CKD-MBD is best accomplished with quantitative bone histomorphometry. Biochemical markers, especially intact parathyroid hormone and bone-specific alkaline phosphatase, also may be helpful. When the diagnosis of osteoporosis is established, management in stages 4-5 CKD may include antiresorptive or anabolic agents, though evidence for efficacy is marginal in advanced CKD. © 2014 by the National Kidney Foundation, Inc.
Raza H.,Health Science University
FEBS Journal | Year: 2011
Glutathione (GSH) conjugating enzymes, glutathione S-transferases (GSTs), are present in different subcellular compartments including cytosol, mitochondria, endoplasmic reticulum, nucleus and plasma membrane. The regulation and function of GSTs have implications in cell growth, oxidative stress as well as disease progression and prevention. Of the several mitochondria localized forms, GSTK (GST kappa) is mitochondria-specific since it contains N-terminal canonical and cleavable mitochondria targeting signals. Other forms like GST alpha, mu and pi purified from mitochondria are similar to the cytosolic molecular forms or 'echoproteins'. Altered GST expression has been implicated in hepatic, cardiac and neurological diseases. Mitochondria-specific GSTK has also been implicated in obesity, diabetes and related metabolic disorders. Studies have shown that silencing the GSTA4 (GST alpha) gene resulted in mitochondrial dysfunction, as was also seen in GSTA4 null mice, which could contribute to insulin resistance in type 2 diabetes. This review highlights the significance of the mitochondrial GST pool, particularly the mechanism and significance of dual targeting of GSTA4-4 under in vitro and in vivo conditions. GSTA4-4 is targeted in the mitochondria by activation of the internal cryptic signal present at the C-terminus of the protein by protein-kinase-dependent phosphorylation and cytosolic heat shock protein (Hsp70) chaperone. Mitochondrial GST pi, on the other hand, has been shown to have two uncleaved cryptic signals rich in positively charged amino acids at the N-terminal region. Both physiological and pathophysiological implications of GST translocation to mitochondria are discussed in the review. This paper is part of a minireview series on bimodal targeting of proteins in the mitochondria and other compartments. Glutathione S-transferases (GSTs) are a family of enzymes present in the cytosol, mitochondria, endoplasmic reticulum, nucleus and plasma membrane. They play a significant role in cell growth and toxicity. Both physiological and pathophysiological implications of GST compartmentalization have been discussed © 2011 The Author Journal compilation © 2011 FEBS.
Ohira K.,Health Science University
Cellular and Molecular Life Sciences | Year: 2011
It has been accepted that new neurons are added to the olfactory bulb and the hippocampal dentate gyrus throughout life in the healthy adult mammalian brain. Recent studies have clarified that brain insult raises the proliferation of neural stem cells/neural progenitor cells existing in the subventricular zone and the subgranular zone, which become sources of new neurons for the olfactory bulb and the dentate gyrus, respectively. Interestingly, convincing data has shown that brain insult invokes neurogenesis in various brain regions, such as the hippocampal cornu ammonis region, striatum, and cortex. These reports suggest that neural stem cells/ neural progenitor cells, which can be activated by brain injury, might be broadly located in the adult brain or that new neurons may migrate widely from the neurogenic regions. This review focuses on brain insult-induced neurogenesis in the mammalian forebrain, especially in the neocortex. © Springer Basel AG 2010.
Miller P.D.,Health Science University
Bone | Year: 2011
Bisphosphonates are eliminated from the human body by the kidney. Renal clearance is both by glomerular filtration and proximal tubular secretion. Bisphosphonates given rapidly in high doses in animal models have induced a variety of adverse renal effects, from glomerular sclerosis to acute tubular necrosis. Nevertheless in the doses that are registered for the management of postmenopausal osteoporosis (PMO), oral bisphosphonates have never been shown to adversely affect the kidney, even (in post-hoc analysis of clinical trial data) down to estimated glomerular filtration rates of 15. ml/min. In addition fracture risk reduction has also been observed in these populations with stage 4 chronic kidney disease (CKD) with age-related reductions in glomerular filtration rate (GFR). Intravenous zoledronic acid is safe when the infusion rate is no faster than 15. min though there have been short-term (days 9-11 post-infusion) increases in serum creatinine concentrations in a small sub-set of patients from the postmenopausal registration trials. For these reasons intravenous zoledronic acid should be avoided in patients with GFR levels < 35. ml/min; and the patients should be well hydrated and have avoided the concomitant use of any agent that may impair renal function. Intravenous ibandronate has not to date been reported to induce acute changes in serum creatinine concentrations in the PMO clinical trial data, but the lack of head-to-head comparative data between ibandronate and zoledronic acid precludes knowing if one intravenous bisphosphonate is safer than the other. In patients with GFR levels < 30-35. ml/min, the correct diagnosis of osteoporosis becomes more complex since other forms of renal bone disease, which require different management strategies than osteoporosis, need to be excluded before the assumption can be made that fractures and/or low bone mass are due to osteoporosis. In addition, in patients who may have pre-existing adynamic renal bone disease, there is a lack of evidence of any beneficial effect or harm by reducing bone turnover by any pharmacological agent, including bisphosphonates on bone strength or vascular calcification. Bisphosphonates are safe and effective for the management of osteoporosis when used in the right dose and in the right patient population for the right duration. © 2011 Elsevier Inc.
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: STTR | Phase: Phase I | Award Amount: 149.96K | Year: 2015
DESCRIPTION provided by applicant This Small Business Technology Transfer STTR Phase I project proposes to develop autonomously bioluminescent human stem cells for continuous reagent free and real time bioimaging to address the National Institutes of Healthandapos s request for new techniques for non invasive long term tracking of stem cell survivability engraftment and migration following in vivo implantation The ability of stem cells to self renew and differentiate into other cell lineages has emerged as a valuable therapeutic approach to functionally heal previously irreparable tissues and organs However for the regenerative medicine field to effectively transition toward translational and clinical practice outcomes a strong dependence on animal models will be required to fully understand the capabilities and complexities of stem cells BioTech proposes to expand the informational capacity of animal models by creating stem cell lines that self generate bioluminescent light via expression of a andapos humanizedandapos bacterial luciferase thereby enabling stem cells to be continuously imaged throughout their lifetime as they physiologically function within their animal host This differs significantly from the current market of bioluminescent imaging technologies that rely on a firefly luciferase gene construct that must be provided with a chemical substrate to activate its light emission response resulting in only marginally informative single time point snapshots of cell function in tandem with repetitive animal injections that invoke unknown and potentially interfering interactions and adversely effects animal welfare In partnership with the University o Tennessee Medical Center the specific objectives of this Randamp D effort are to develop piggyBac transposition and lentiviral transduction methods for streamlined integration of the bioluminescent phenotype into adipose derived mesenchymal stem cell lines followed by performance evaluation in in vitro D scaffolds and in vivo mouse models to demonstrate proficiency toward uninterrupted imaging and enriched data flows that far exceed that of existing firefly luciferase methods With no change in instrumentation or fundamental bioluminescent protocols necessary researchers can seamlessly transition from firefly luciferase to BioTechandapos s humanized bacterial luciferase technology to advance their in vivo experimental Randamp D to more informative endpoints with fewer animals required The contribution of this innovative imaging platform to the field of regenerative medicine will provide more physiologically relevant and representative data critical to predicting the efficacy and safety of treatment strategies as they precede to clinical trials PUBLIC HEALTH RELEVANCE Regenerative medicine using stem cell therapies to replenish and restore tissues and organs has the potential to transform human health by curing and remedying previously unmanageable diseases Animal studies have played significant roles in deciphering the therapeutic capacity of stem cells but there exists a disparity between the results obtained from animal experiments and their transition to human clinical trials that are impeding advancements in the regenerative medicine field To increase the amount of experimental information obtainable from animal models BioTech proposes to create stem cell lines that continuously emit bioluminescent light thereby enabling implanted stem cells to be visualized and tracked throughout their lifetime for improved understanding of their therapeutic potential and limitations directly within living animal subjects